Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1 11Phase 3 5Phase 1/2 4Phase 2/3 2Phase EARLY_PHASE1 1Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Myelodysplastic Syndromes 1

Interventions

pembrolizumab 4Nivolumab 4Magnetic Resonance Spectroscopy 4Temozolomide 2Specimen Handling 2Rituximab 2Radiotherapy 2Radiosurgery 2Paclitaxel 2Neoadjuvant Therapy 2Gemcitabine 2Dexamethasone 2Cisplatin 2Carboplatin 2venetoclax 1theanine 1temsirolimus 1tafasitamab 1sugemalimab 1senicapoc 1sacituzumab govitecan 1ruxolitinib 1perampanel 1paricalcitol 1pamiparib 1olaparib 1lutetium Lu 177 dotatate 1irinotecan sucrosofate 1glofitamab 1gadobutrol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Azacitidine × 30 days × Clear all
NCT04187703 2026-05-18

5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Recruiting
20 enrolled
Myeloid

Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡